DelveInsight's Hidradenitis Suppurativa Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hidradenitis Suppurativa (HS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hidradenitis Suppurativa (HS) Epidemiology Forecast - 2032

Key Highlights
<ul>
<li>Low disease awareness and associated misdiagnoses and under-reporting by patients because of shame and embarrassment have contributed to substantial delays in diagnosis, reported to be between 7 and 10 years on average. The course of the disease is often unpredictable, which can be challenging for patients and healthcare professionals (HCPs) in managing hidradenitis suppurativa.</li>
<li>According to secondary research, the widely reported prevalence rate is 0.03-4%. This disparity could be explained by differences in research design (for example, prospective vs. retrospective studies or registry-based vs. self-reported questionnaire-based studies).</li>
<li>The Gender-specific analysis suggests that Hidradenitis Suppurativa is more common in females than males in the US and Europe but in Japan, it is more prevalent in males than females.</li>
<li>According to DelveInsight&rsquo;s analysis, the highest proportion of Hidradenitis Suppurativa prevalent pool was observed in the 30&ndash;39 age group among the 7MM.</li>
<li>According to Hurley&rsquo;s classification, Hidradenitis Suppurativa can be classified into stages, i.e., Stage I, II, and III. The most prevalent cases are estimated to be at Stage I.</li>
</ul>
&nbsp;
DelveInsight&rsquo;s &ldquo;Hidradenitis Suppurativa &ndash; Epidemiology Forecast &ndash; 2032&rdquo; report delivers an in-depth understanding of Hidradenitis Suppurativa, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Geography Covered
<ul>
<li>The United States</li>
<li>EU4 (Germany, France, Italy, and Spain) and the United Kingdom</li>
<li>Japan</li>
</ul>
Study Period: 2019&ndash;2032
<h2>Hidradenitis Suppurativa Disease Understanding and Diagnostic Algorithm</h2>
Hidradenitis Suppurativa Overview
Hidradenitis Suppurativa is a complex dermatological disease characterized by recurrent painful nodules and suppuration in areas such as the axilla and groin. It is also known as Acne inversa, and there is no biological or pathological test to facilitate diagnosis; its clinical features and chronicity can define it.
&nbsp;
The underlying cause of hidradenitis suppurativa is unknown, but the condition probably results from genetic and environmental factors.
&nbsp;
Hidradenitis Suppurativa Diagnosis
The diagnosis is primarily clinical, based on symptoms reported by the patient and signs observed by the physician. No pathognomonic test exists; a biopsy is rarely required, especially in well-developed lesions. Primary diagnosis of hidradenitis suppurativa involves identifying the disease and assessing its comorbidities.
&nbsp;
Fulfillment of three criteria is necessary for the diagnosis of Hidradenitis suppurativa, which includes-&nbsp; typical lesions (deep-seated, painful nodules), characteristic distribution or typical anatomical predilection (i.e., axillae, groins, perineal and perianal regions, buttocks, infra-mammary and inter-mammary folds), and recurrence (Chronicity and recurrence of lesions). Arbitrarily, two recurrences over 6 months have been used as a qualifier for a diagnosis. All three criteria must be present for the definitive diagnosis. Smoking is a significant association, and cessation is important for disease control. Approximately one-third of patients with hidradenitis suppurativa have a family history of the disease.
Further details related to diagnosis are provided in the reported
<h2>Hidradenitis Suppurativa Epidemiology</h2>
As the market is derived using a patient-based model, the Hidradenitis Suppurativa epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Hidradenitis Suppurativa, total diagnosed prevalent cases of Hidradenitis Suppurativa, Gender-specific prevalent cases of Hidradenitis Suppurativa, Age-specific prevalent cases of Hidradenitis Suppurativa, Stage-specific prevalent cases of Hidradenitis Suppurativa and Treated prevalent cases of Hidradenitis suppurativa in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032. The total prevalent cases of Hidradenitis Suppurativa in the 7MM comprised approximately 6.2 million cases in 2022 and are projected to increase during the forecast period.
<ul>
<li>In 2019, the total prevalent cases of Hidradenitis Suppurativa were approximately 2.8 million cases in the US, which is expected to grow during the study period, i.e., 2019&ndash;2032.</li>
<li>In the 7MM, the US contributed to the maximum diagnosed prevalent cases acquiring approximately 48% of cases in 2022. Germany accounted for approximately 13%, and Japan accounted for approximately 4% of the diagnosed prevalent cases.</li>
<li>Among EU4 and the UK, Germany accounted for the highest number of Hidradenitis Suppurativa prevalent cases, while Spain accounted for the least prevalent cases.</li>
<li>In the US, approximately 25% of the patient share is attributed to males and 75% to females, whereas in Japan, approximately 70% patient share is attributed to males and around 30% to females.</li>
</ul>
<h2>KOL Views</h2>
To keep up with current market trends, we take KOLs and SMEs&rsquo; opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts contacted to understand and validate the patient pool, and forecasted trends included Centers such as the University of California, San Francisco, School of Medicine; CHA Bundang Medical Center, CHA University School of Medicine, and other organizations.
DelveInsight&rsquo;s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM.
Unlock comprehensive insights! Click Here to Purchase the Full Report @&nbsp;<a style="color: #e03e2d;" href="https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market">Hidradenitis Suppurativa Drugs Market</a>
<h2>Scope of the Report</h2>
<ul>
<li>The report covers a segment of key events, an executive summary, and a descriptive overview of Hidradenitis Suppurativa, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.</li>
<li>Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.</li>
<li>A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.</li>
</ul>
Hidradenitis Suppurativa Report Insights
<ul>
<li>Patient population</li>
<li>Prevalence pattern</li>
<li>Diagnosis rate</li>
<li>Countrywise epidemiology distribution</li>
</ul>
<h2>Hidradenitis Suppurativa Report Key Strengths</h2>
<ul>
<li>Ten years forecast</li>
<li>The 7MM coverage</li>
<li>Hidradenitis Suppurativa epidemiology segmentation</li>
<li>Hidradenitis Suppurativa Report Assessment</li>
<li>Epidemiology segmentation</li>
<li>Current diagnostic practices</li>
<li>Unmet needs</li>
</ul>
Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @&nbsp;<a style="color: #e03e2d;" href="https://www.delveinsight.com/report-store/hidradenitis-suppurativa-pipeline-insight">Hidradenitis Suppurativa Approved Drugs</a>
<h2>Key Questions</h2>
Epidemiology Insights
<ul>
<li>What are the disease risk, burdens, and unmet needs of Hidradenitis Suppurativa? What will be the growth opportunities across the 7MM with respect to the patient population of Hidradenitis Suppurativa?</li>
<li>What is the historical and forecasted Hidradenitis Suppurativa patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?</li>
<li>At what CAGR is the population expected to grow in the 7MM during the study period (2019&ndash;2032)?</li>
<li>What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hidradenitis Suppurativa?</li>
<li>What will be the eligible patient pool for treatment out of all prevalent cases?</li>
</ul>
<h2>Reasons to Buy</h2>
<ul>
<li>The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Hidradenitis Suppurativa market.</li>
<li>Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.</li>
<li>To understand the existing market opportunity in varying geographies and the growth potential over the coming years.</li>
<li>To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis, current diagnosis rate, and treatment-eligible patient pool.</li>
<li>Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.</li>
</ul>
 Stay Updated with us for new articles @ <a style="color: #e03e2d;" href="https://www.delveinsight.com/blog/">Latest DelveInsight Blogs</a>

1. Key Insights
2. Report Introduction
3. Hidradenitis Suppurativa Market Overview at a Glance
3.1. Market Share by Therapies (%) Distribution of Hidradenitis Suppurativa in 2019
3.2. Market Share by Therapies (%) Distribution of Hidradenitis Suppurativa in 2032
4. Executive Summary of Hidradenitis Suppurativa
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Overview: Hidradenitis Suppurativa
7.1. Introduction
7.2. Causes and Symptoms of Hidradenitis Suppurativa
7.3. Classification and Severity Assessment of Hidradenitis Suppurativa
7.3.1. Hurley Stages of hidradenitis suppurativa
7.3.2. Modified Sartorius Score (MSS) of hidradenitis suppurativa
7.3.3. Physician Global Assessment of Hidradenitis Suppurativa
7.3.4. Specific Severity Index of Hidradenitis Suppurativa (HSSI)
7.4. Pathophysiology of Hidradenitis Suppurativa
7.5. Genetic Basis of Hidradenitis Suppurativa
7.6. Diagnosis of Hidradenitis Suppurativa
7.6.1. Differential Diagnoses
7.7. Biomarkers of Hidradenitis Suppurativa
7.8. Risk Factors and Complications
7.9. Comorbidities
8. Treatment and Guidelines
8.1. European S1 Guideline for the Treatment of Hidradenitis Suppurativa/Acne Inversa: (2015)
8.1.1. Medical therapy
8.1.2. Surgical therapy
8.2. North American Clinical Management Guidelines for Hidradenitis Suppurativa: (2019)
8.2.1. Diagnosis, evaluation, and the use of complementary and procedural management
8.2.2. Topical, intralesional, and systemic medical management
8.3. British Association of Dermatologists Guidelines for the Management of Hidradenitis Suppurativa (Acne Inversa): (2018)
8.4. Guidelines for the Management of Hidradenitis Suppurativa: Recommendations Supported by the Centre of Evidence of the French Society of Dermatology: (2021)
8.5. Hidradenitis Suppurativa/Acne Inversa: A Practical Framework for Treatment Optimization &ndash; Systematic Review and Recommendations from the Hidradenitis Suppurativa Alliance Working Group: (2018)
9. Epidemiology and Patient Population
9.1. Assumptions and Rationale: The 7MM
9.2. Key Findings
9.3. Total Prevalent Cases of Hidradenitis Suppurativa in the 7MM
9.4. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the 7MM
9.5. The United States
9.5.1. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the United States
9.5.2. Gender-Specific Prevalent Cases of Hidradenitis Suppurativa in the United States
9.5.3. Age-specific Prevalent Cases of Hidradenitis Suppurativa in the United States
9.5.4. Stage-specific Prevalent Cases of Hidradenitis Suppurativa in the United States
9.5.5. Treated Prevalent Cases of Hidradenitis Suppurativa in the United States
9.6. EU4 and the UK
9.6.1. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the EU4 and the UK
9.6.2. Gender-specific Prevalent Cases of Hidradenitis Suppurativa in EU4 and the UK
9.6.3. Age-specific Cases of Hidradenitis Suppurativa in EU4 and the UK
9.6.4. Stage-specific Cases of Hidradenitis Suppurativa in EU4 and the UK
9.6.5. Treated Prevalent Cases of Hidradenitis Suppurativa in EU4 and the UK
9.7. Japan
9.7.1. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in Japan
9.7.2. Gender-specific Prevalent Cases of Hidradenitis Suppurativa in Japan
9.7.3. Age-specific Prevalent Cases of Hidradenitis Suppurativa in Japan
9.7.4. Stage-specific Prevalent Cases of Hidradenitis Suppurativa in Japan
9.7.5. Treated Prevalent Cases of Hidradenitis Suppurativa in Japan
10. KOL Views
11. Unmet Needs
12. Appendix
12.1. Bibliography
12.2. Acronyms and Abbreviations
12.3. Report Methodology
13. DelveInsight Capabilities
14. Disclaimer
15. About DelveInsight

DelveInsight’s “Hidradenitis Suppurativa Epidemiology Forecast 2032” report delivers an in-depth understanding of Hidradenitis Suppurativa, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Hidradenitis Suppurativa Epidemiology

Hidradenitis Suppurativa Epidemiology Forecast - 2032

DelveInsight's Hidradenitis Suppurativa Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, forecasted epidemiology of HS in the US, EU5, and Japan.